HSBC Holdings plc set a CHF 90 price target on Novartis AG (VTX:NOVN) in a report published on Tuesday. The brokerage currently has a buy rating on the stock.

NOVN has been the topic of several other reports. UBS AG set a CHF 78 price objective on shares of Novartis AG and gave the stock a neutral rating in a research note on Monday, August 28th. Goldman Sachs Group, Inc. (The) set a CHF 80 price objective on shares of Novartis AG and gave the stock a neutral rating in a research note on Wednesday, June 14th. Kepler Capital Markets set a CHF 87 price objective on shares of Novartis AG and gave the stock a buy rating in a research note on Monday, August 28th. Jefferies Group LLC set a CHF 103 price objective on shares of Novartis AG and gave the stock a buy rating in a research note on Friday, June 23rd. Finally, Deutsche Bank AG set a CHF 80 price objective on shares of Novartis AG and gave the stock a neutral rating in a research note on Friday, July 7th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and seven have issued a buy rating to the company. The company currently has a consensus rating of Hold and a consensus price target of CHF 85.

Shares of Novartis AG (VTX NOVN) opened at 83.00 on Tuesday. The firm has a market capitalization of CHK 194.46 billion and a P/E ratio of 30.30. Novartis AG has a 12 month low of CHK 67.40 and a 12 month high of CHK 84.35. The stock has a 50 day moving average price of CHK 81.20 and a 200 day moving average price of CHK 78.64.

COPYRIGHT VIOLATION WARNING: This news story was first published by Watch List News and is owned by of Watch List News. If you are accessing this news story on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be accessed at https://www.watchlistnews.com/novartis-ag-novn-given-a-chf-90-price-target-by-hsbc-holdings-plc-analysts/1574946.html.

About Novartis AG

Novan, Inc, a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris.

Analyst Recommendations for Novartis AG (VTX:NOVN)

Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with Analyst Ratings Network's FREE daily email newsletter.